慢性糜烂性胃炎予以瑞巴派特联合艾司奥美拉唑治疗对患者MTL、GAS水平改善研究
|
徐婉丽
|
武汉市第八医院（武汉市肛肠医院），湖北武汉，430000
|
摘要：目的 分析慢性糜烂性胃炎予以瑞巴派特联合艾司奥美拉唑治疗对患者MTL、GAS水平改善研究。方法 选择2024年1月-2025年1月我院收治慢性糜烂性胃炎患者100例，等比分配为对照组和观察组各50 例。对照组给予瑞巴派特治疗，观察组给予瑞巴派特联合艾司奥美拉唑治疗。对比两组患者消化功能和胃黏膜情况。结果 治疗后，两组患者MTL、GAS水平低于治疗前，且观察组的 MTL、GAS水平降低幅度大于对照组，P<0.05；治疗后，观察组PGE2 水平高于对照组，胃黏膜中性粒细胞浸润评分、胃黏膜单核细胞浸润评分低于对照组，P<0.05。结论 瑞巴派特联合艾司奥美拉唑治疗慢性糜烂性胃炎可以有效改善MTL、GAS水平。
关健词：慢性糜烂性胃炎；瑞巴派特；艾司奥美拉唑
|
A Study on the Improvement of MTL and GAS Levels in Patients with Chronic Erosive Gastritis Treated with Rebamipide Combined with Esomeprazole
|
Wanli Xu
Wuhan Eighth Hospital (Wuhan Anorectal Hospital), Wuhan Hubei 430000，China
|
Abstract： Objective To analyze the effects of Rebamipide combined with Esomeprazole in the treatment of chronic erosive gastritis on the improvement of patients’ MTL and GAS levels.Methods A total of 100 patients with chronic erosive gastritis admitted to our hospital from January 2024 to January 2025 were selected and equally divided into a control group and an observation group, with 50 cases in each group. The control group was treated with Rebamipide, while the observation group was treated with Rebamipide combined with Esomeprazole. The digestive function and gastric mucosa condition of the two groups were compared.Results After treatment, the MTL and GAS levels in both groups were lower than before treatment,and the reduction in MTL and GAS levels in the observation group was greater than that in the control group (P<0.05). After treatment, the PGE2 level in the observation group was higher than that in the control group, while the gastric mucosa neutrophil infiltration score and gastric mucosa monocyte infiltration score were lower than those in the control group (P<0.05).Conclusion Rebamipide combined with Esomeprazole in the treatment of chronic erosive gastritis can effectively improve MTL and GAS levels.
Keywords : Chronic erosive gastritis; Rebamipide; Esomeprazole
参考文献
[1] 郭霞, 陈名. 慢性糜烂性胃炎采用瑞巴派特联合艾司奥美拉唑治疗的效果及对消化功能、胃黏膜的影响观察[J]. 中国实用医药,2025,20(07):79-81.
[2] 李艳歌, 董齐燕, 周莹. 藿朴夏苓汤加减联合瑞巴派特治疗慢性糜烂性胃炎患者的效果[J]. 中国民康医学,2025,37(05):114-117.
[3] 辛承益, 张劲, 王颖, 等. 瑞巴派特联合泮托拉唑治疗幽门螺杆菌阴性慢性糜烂性胃炎的临床疗效及药学分析[J]. 中国医药科学,2024,14(01):125-128.
[4] 李平学, 邓瑛. 瑞巴派特联合雷贝拉唑对慢性糜烂性胃炎患者胃黏膜炎症反应的影响[J]. 现代诊断与治疗,2023,34(05):654-656.
[5] 刘雄蔚. 瑞巴派特与艾司奥美拉唑联合应用于慢性糜烂性胃炎患者的效果分析[ J ] . 中国医药指南,2023,21(03):98-100.
[6] 张海芳, 贾淑娟, 张娟, 等. 瑞巴派特联合泮托拉唑治疗幽门螺杆菌阴性慢性糜烂性胃炎的临床疗效分析[J]. 中国全科医学,2021,24(S1):108-110.
[7] 孙伟红, 张慧敏. 瑞巴派特对慢性糜烂性胃炎的治疗效果[J]. 河南医学研究,2020,29(22):4127-4128.
[8] 刘庆东, 赵纯梅, 王蒙, 等. 泮托拉唑联合瑞巴派特治疗慢性糜烂性胃炎的疗效[ J ] . 贵州医药,2019,43(11):1765-1766.
|
|
|
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
|
|
